BioMedNewsBreaks

ThursdayDec 11, 2025 11:33 am

BioMedNewsBreaks — Volition Solves Liquid Biopsy’s “Needle in a Haystack” Problem; Achieves 180-fold (18,000%) Enrichment

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced the preprint release of research introducing Capture-Seq(TM), a new method for analyzing transcription factor–protected ultrashort DNA fragments in blood as potential low-cost cancer biomarkers. The manuscript, titled “Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq,” highlights Volition’s achievement of 180-fold enrichment of transcription factor–bound fragments by focusing on DNA in its natural chromosomal context rather than on chemically extracted DNA, overcoming the longstanding challenge of overwhelming background DNA in liquid biopsy testing. Early findings from a 70-person training cohort showed 100 percent sensitivity and 100 percent…

Continue Reading

WednesdayDec 10, 2025 9:20 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, is highlighted in a new NetworkNewsAudio APR titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now.” The feature underscores the growing impact of chronic and rare conditions on older adults, with more than 30 million Americans affected and most lacking FDA-approved therapies. Soligenix’s lead candidate, HyBryte(TM) for cutaneous T-cell lymphoma, is now in the final confirmatory trial needed before global marketing submissions, placing the Company’s progress at a key point as the administration advances new health policy initiatives related to chronic and…

Continue Reading

WednesdayDec 10, 2025 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment after successfully appealing a prior NSE determination. The patented cable-free technology captures cardiac electrical signals in three non-coplanar dimensions to generate a synthesized 12-lead ECG that can be reviewed remotely by a board-certified cardiologist, enabling patients to capture meaningful ECG data wherever symptoms occur. With clearance in hand, HeartBeam plans a limited U.S. launch in early 2026 with select cardiology groups, alongside advancing programs in heart attack detection, development of an on-demand…

Continue Reading

TuesdayDec 09, 2025 2:29 pm

BioMedNewsBreaks — Caring Brands, Inc. (NASDAQ: CABR) Closes $4 Million Offering as Company Uplists to Nasdaq Capital Market

Caring Brands (NASDAQ: CABR) closed its underwritten U.S. public offering of 1,000,000 shares of common stock at $4.00 per share for gross proceeds of about $4 million before underwriting discounts and expenses, completing the Company’s uplisting to the Nasdaq Capital Market, where its shares began trading on Nov. 13, 2025. Caring Brands granted the underwriter a 45-day option to purchase up to 150,000 additional shares and intends to use net proceeds for general working capital, marketing and sales of its proprietary products, and repayment of certain debt. To view the full press release, visit https://ibn.fm/y2EXR About Caring Brands, Inc. Caring Brands…

Continue Reading

MondayDec 08, 2025 2:15 pm

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Appoints Duncan McGillivray as Chief Operating Officer

HealthLynked (OTCQB: HLYK) announced the appointment of Duncan McGillivray, MBA, as Chief Operating Officer. McGillivray brings more than 30 years of leadership across healthcare, technology, capital markets, and project finance. He will oversee operational scale-up, support national payer and employer partnerships, and lead capital formation and banking relations as the company advances its planned Nasdaq Capital Market uplisting. To view the full press release, visit https://ibn.fm/jFAqD About HealthLynked Corp. HealthLynked Corp. enhances healthcare through personalized care management that improves outcomes and reduces costs. Its cloud-based platform connects patients with providers for virtual or in-office appointments and consolidates medical records into…

Continue Reading

FridayDec 05, 2025 10:09 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies 

Soligenix (NASDAQ: SNGX), announces its inclusion in a BioMedWire editorial examining the urgent rise of chronic and rare diseases in aging populations. With more than 30 million Americans living with rare disorders that often lack FDA-approved treatments, demand for novel therapies continues to grow. Soligenix is advancing late-stage programs including HyBryte(TM) for cutaneous T-cell lymphoma, now in its final confirmatory trial, positioning the Company at the intersection of scientific innovation and evolving national health-policy priorities focused on chronic and rare conditions. To view the full press release, visit https://ibn.fm/lPJrx About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on…

Continue Reading

ThursdayDec 04, 2025 11:45 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) identifies Biomarker Signature Predicting Sensitivity to IV Sapu003

Oncotelic Therapeutics (OTCQB: OTLC), reports that its 45% owned joint venture, Sapu Nano, has identified a High-RICTOR/Low-RPTOR molecular signature that predicts tumor sensitivity to Sapu003, the company’s intravenous Deciparticle(TM) formulation of everolimus. The biomarker framework, to be presented at the 2025 San Antonio Breast Cancer Symposium, is based on analysis of more than 9,000 tumor samples across 20 cancer types and represents the first prospective selection strategy for IV everolimus. Data show that mTORC2-dominant tumors — including HR+/HER2- breast, lung adenocarcinoma, gastric, renal, ovarian, AML and T-cell malignancies — exhibit heightened mTOR dependency and predicted sensitivity to Sapu003, which overcomes…

Continue Reading

ThursdayDec 04, 2025 10:01 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Nu.Q NETs Assay Selected for France’s National Sepsis Detection Initiative

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that its Nu.Q® NETs H3.1 assay has been chosen as the sole biomarker for “DETECSEPS,” a French government-funded evaluation of early sepsis detection under the France 2030 plan. The program, led by the IHU SEPSIS and supported by a €6.3 million (~$7.3 million) grant, aims to transform emergency care for patients with infection and risk of sepsis progression. Professor Djillali Annane, Intensive Care Department, IHU SEPSIS, Raymond Poincaré Hospital (AP-HP) and Scientific Director of DETECSEPS, noted that combining Volition’s Nu.Q® H3.1 biomarker with a clinical score (NEWS2) could improve…

Continue Reading

WednesdayDec 03, 2025 12:26 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% JV Reports IV Sapu003 Cuts GI Exposure to Everolimus by Up to 67-Fold 

Oncotelic Therapeutics (OTCQB: OTLC), 45% owner of the Sapu Nano joint venture, announced new pharmacokinetic and tissue-distribution data showing that Sapu003, its intravenous Deciparticle (TM) formulation of everolimus, dramatically reduces gastrointestinal drug accumulation compared with oral everolimus. Oral dosing drives extreme gut exposure—up to 2,448× plasma levels in the stomach—while IV Sapu003 limits GI tissue levels to just 36–48× plasma, representing reductions of up to 67-fold. The company stated that this shift may improve tolerability, maintain the drug’s intrinsic metabolic profile, and provide more consistent systemic exposure. To view the full press release, visit https://ibn.fm/dVPuX About Oncotelic Therapeutics Inc. Oncotelic Therapeutics…

Continue Reading

WednesdayDec 03, 2025 11:45 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with highlights from a recent webinar. The study in 63 heavily pre-treated patients with advanced solid tumors met all primary endpoints for safety and tolerability and established a clear recommended Phase 2 dose. Encouraging signals of durable disease control were observed, particularly in tumors with DNA damage repair pathway deficiencies. Building on these results, Lantern is advancing multiple biomarker-guided Phase 1b/2 trials across triple-negative breast cancer,…

Continue Reading